Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels.
about
Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawalSustained-Release Naltrexone For Opioid DependenceEvidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intakeA placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption.Opiate detoxification under anaesthesia. No confusion and distress were intended.Opioid dependence treatment: options in pharmacotherapy.Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment.Rapid opiate detoxification and antagonist induction under general anaesthesia or intravenous sedation is humane, sometimes essential and should always be an option. Three illustrative case reports involving diabetes and epilepsy and a review of theExtended release drug delivery strategies in psychiatry: theory to practiceImproved parameters of metabolic glycaemic and immune function and arterial stiffness with naltrexone implant therapy.Pharmacological enhancement of naltrexone treatment for opioid dependence: a reviewLearning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive "immersion" methods of foreign language teaching.The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practiceInfecting the brain to stop addiction?Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting.Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program.Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?Opioid maintenance: a comparative review of pharmacological strategies.Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres.Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.Long-acting Preparations in Substance Abuse Management: A Review and Update.Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals.The science and practice of medication-assisted treatments for opioid dependence.Chronic pain and ultrarapid opioid detoxification.Constitutive opioid receptor activation: a prerequisite mechanism involved in acute opioid withdrawal.Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology.
P2860
Q24240954-AFCD192E-488B-4132-B69A-27467E3A2AD7Q24243205-6212A006-D19F-4559-BFB3-5253E4C7EC78Q24651508-42543350-302D-4497-B14E-8FCF2D10000EQ33556479-4568BA9D-CCA4-4373-A4CE-938DB2656112Q33747985-9541EA2E-54F5-44C6-83FC-07DDC59582ACQ33816272-2F355582-6D4C-43AF-9E5F-643AD5613DE6Q33868638-C156F257-0F49-40B4-956A-5BCF87CDE591Q34280076-9A680D0A-ECB1-485E-85AC-94484FDBF40FQ34371727-722D1114-4DDA-4D5C-BAD8-CDE1CBEF3604Q34396625-8AE55D92-058A-4652-9648-199B9F265252Q34525271-B9140D50-79B8-4B6D-B80E-F29F97F8C95BQ35084340-D2A9E054-F5CA-432F-A44D-75C5B706E6D3Q35197255-6EDF96DE-E8F2-4B98-A180-DA8ECB9293B6Q35491054-6CF15161-3E74-4670-8548-4854DF0A72FDQ35571120-C9214BAE-A8E5-473E-903B-8A27F7503615Q35847447-B5862946-4456-4ACB-A6EA-38B8C929D5CCQ36326197-84F92811-4FDF-4694-9114-F7BABB9AD6E2Q36398092-3FBCE521-4CE7-495C-932E-31C34F6D51A9Q36664852-67C23177-F229-4CF1-AC1D-442C81C4DF65Q36681297-6D77D444-A0EA-4542-B4A8-951564AF6CF5Q37205726-BFE590B7-4BBF-4642-8BE8-B6DB85CD5E39Q37873579-6A5C2413-FD0A-4C51-A78C-71F5C3A9A751Q38119942-8B0E7813-A985-47B1-B02A-70D03AB05E14Q38936254-D9FCCED0-0C7E-4643-9DA6-759481AB9125Q39223925-F89F4A3B-E574-45C9-8F3F-A77B5802B71FQ44333120-4F8E72E1-B8E0-47A9-8712-B61583F2EC8AQ44350494-43A5010D-F05D-4A66-85D3-4B3379848F9BQ51937580-4C93182D-C521-4449-886F-2B95796C7684
P2860
Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Naltrexone implants can comple ...... te on naltrexone blood levels.
@en
Naltrexone implants can completely prevent early
@nl
type
label
Naltrexone implants can comple ...... te on naltrexone blood levels.
@en
Naltrexone implants can completely prevent early
@nl
prefLabel
Naltrexone implants can comple ...... te on naltrexone blood levels.
@en
Naltrexone implants can completely prevent early
@nl
P2093
P2860
P1433
P1476
Naltrexone implants can comple ...... te on naltrexone blood levels.
@en
P2093
Colin Brewer
John Foster
Terry Steele
P2860
P304
P356
10.1080/1355621031000117446
P577
2003-06-01T00:00:00Z